Company intelligence / Profile preview

Actineer

Chalk River, Ontario, Canada

Ownership: Private
Development stage: Other

Overview

Actineer is not developing drugs directly but has achieved cyclotron-based production of Actinium-225 for use in targeted alpha therapy; it expects to provide GMP-grade Ac-225 for clinical trials and commercial radiopharmaceutical applications by mid-2025.

Therapeutic areas: Oncology
Modalities: RadiopharmaceuticalTargeted alpha therapy precursorAlpha-emitter
Industry: Chemicals & Materials

Partnerships

ITM Isotope Technologies Munich SE (co-founder/parent)Canadian Nuclear Laboratories (co-founder/parent)Atomic Energy of Canada Limited (via CNL)

Beyond the preview

Go deeper on Actineer.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Actineer.

Explore the full profile